Sanofi is to take on Boehringer Ingelheim's consumer health division in exchange for ... a good fit with its existing business in terms of products and geographies, giving it much increased ...

Sanofi is following in the footsteps of ... said the pharma group. The range of consumer healthcare products it offers will also be “streamlined” ahead of the spin-off. According to the ...

The consumer health unit of Sanofi boasts a portfolio inclusive of popular over-the-counter products like Phytoxil cough syrups, Icy Hot pain relief gels, and Dulcolax laxative tablets.

Also Read: Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And ... listed entity headquartered in France. The consumer-healthcare business employs some 11,000 people.

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

Sanofi Consumer Healthcare India Limited, listed on BSE and NSE, focuses on consumer healthcare with popular brands and ...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.

The Consumer Health spin-out is expected to ... according to Sanofi's earnings press release. Sanofi markets and sells >30 major drug products, although only two drugs, Dupixent and the company's ...

Sanofi Consumer Healthcare India has been listed on the BSE and NSE following its demerger from Sanofi India. The listing marks a significant milestone for the company, as it aims to capitalize on ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

Sanofi Consumer Healthcare India Limited (SCHIL) is successfully listed on BSE Limited (BSE) and National Stock Exchange of India Limited (NSE). The milestone was marked with the ringing of the ...